| Literature DB >> 34742287 |
Qiao-Yan Lian1, Ao Chen1, Jian-Heng Zhang1, Wei-Jie Guan1, Xin Xu1, Bing Wei1, Dan-Xia Huang1, Jian-Xing He2, Chun-Rong Ju3.
Abstract
BACKGROUND: High-throughput next-generation sequencing (HT-NGS) has the potential to detect a large variety of pathogens; however, the application of HT-NGS in lung transplant (LTx) recipients remains limited. We aimed to evaluate the value of HT-NGS for pathogen detection and diagnosis of pulmonary infection during early-stage post-lung transplantation.Entities:
Keywords: High-throughput next-generation sequencing; Lung transplantation; Pathogen; Pulmonary infection
Mesh:
Year: 2021 PMID: 34742287 PMCID: PMC8572506 DOI: 10.1186/s12890-021-01723-z
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Fig. 1Flow diagram of the study
Demographic and clinical characteristics of 51 lung transplant recipients
| Patient characteristics | Lung transplant recipients, n (%) |
|---|---|
| Age (IQR, year) | 60 (53, 66) |
| Sex | |
| Male | 40 (78.43%) |
| Female | 11 (21.57%) |
| BMI (kg/m2) | 20.82 ± 4.18 |
| Primary disease | |
| COPD | 16 (31.37%) |
| Interstitial lung disease | 25 (49.02%) |
| Bronchiectasis | 5 (9.80%) |
| Eisenmenger syndrome | 2 (3.92%) |
| Pneumosilicosis | 1 (1.96%) |
| BOS | 1 (1.96%) |
| PLAM | 1 (1.96%) |
| Type of lung transplantation | |
| Single lung transplantation | 23 (45.10%) |
| Bilateral lung transplantation | 26 (50.98%) |
| Heart–lung transplantation | 2 (3.92%) |
COPD chronic obstructive pulmonary disease, PLAM pulmonary lymphangioleiomyomatosis, BOS bronchiolitis obliterans syndrome
Fig. 2Comparison of pathogens spectrum identified using conventional microbiological testing and high-throughput next-generation sequencing (HT-NGS). a Pathogen classification categories identified via conventional microbiological testing and HT-NGS. b Pathogen species identified via conventional microbiological testing and HT-NGS
Performance of HT-NGS and conventional microbiological testing in the diagnosis of pulmonary infection in lung transplant recipients
| Infection (35) | Non-infection (16) | Sensitivity% (95%CI) | Specificity% (95%CI) | PPV% (95%CI) | NPV% (95%CI) | ||
|---|---|---|---|---|---|---|---|
| HT-NGS | + | 34 | 11 | 97.14 (83.38–99.85) | 31.25 (12.13–58.52) | 75.56 (60.14–86.61) | 83.33 (36.48–99.12) |
| − | 1 | 5 | |||||
| Conventional microbiological testing | + | 24 | 6 | 68.57 (50.58–82.57) | 62.50 (35.87–83.72) | 80.00 (60.87–91.60) | 47.62 (26.39–69.66) |
| − | 11 | 10 |
HT-NGS high-throughput next-generation sequencing, PPV positive predictive value, NPV negative predictive value
High-throughput next-generation sequencing (HT-NGS) results led to change in treatment strategies
| Patient | Conventional microbiological testing | HT-NGS results(reads) | Changes in treatment strategies | Outcome |
|---|---|---|---|---|
| NO. 9 | Added Ivermectin to the original regimen | Recovery | ||
| NO. 23 | Negative | Changed from Piperacillin sodium tazobactam sodium to Azithromycin and Moxifloxacin | Recovery | |
| NO. 30 | Added Linezolid and Clarithromycin to the original regimen | Recovery |